SCD-O cells should be a useful tool in understanding the complex interactions of steroid hormones with the osteocyte genome, as well as providing a method to understand the alterations in FGF23 expression accompanying diseases including renal failure, vitamin D deficiency, and hypophosphatemic rickets. Here, FGF23 is linked to kidney failure.